Erratum: Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation (Acta Pharmacologica Sinica (2012) 33:5 (682-690) DOI: 10.1038/aps.2012.18);Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation

Acta Pharmacologica Sinica

Volumn 33, Issue 5, 2012, Pages 682-690

  Liu, Dong Bo ^a   Hu, Guang Yuan ^a   Long, Guo Xian ^a   Qiu, Hong ^a   Mei, Qi ^a   Hu, Guo Qing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Celecoxib; Cell cycle; Nasopharyngeal carcinoma; STAT3

Indexed keywords

CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2; PROTEIN BCL 2; PROTEIN MCL 1; STAT3 PROTEIN; SURVIVIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EXPOSURE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; NASOPHARYNX CARCINOMA; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84860785567     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.36     Document Type: Erratum

References (52)

1. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-9. (Pubitemid 35370755)
2. Agulnik M, Epstein JB. Nasophar yngeal carcinoma: current management, future directions and dental implications. Oral Oncol 2008; 44: 617-27.
3. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996; 77: 2423-31. (Pubitemid 26169137)
4. Kim TH, Jeong YI, Jin SG, Pei J, Jung TY, Moon KS, et al. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. Int J Nanomed 2011; 6: 2621-31.
5. Zhang M, Xu ZG, Shi Z, Shao D, Li O, Li W, et al. Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A2 and peroxisome proliferator-activated receptor gamma. Mol Cell Biochem 2011; 355: 233-40.
6. Li H, Liu A, Zhao Z, Xu Y, Lin J, Jou D, et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J Med Chem 2011; 54: 5592-6.
7. Liu Y, Liu A, Li H, Li C, Lin J. Celecoxib inhibits interleukin-6/ interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila Pa) 2011; 4: 1296-305.
8. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-47. (Pubitemid 43983297)
9. Chen WC, McBride WH, Chen SM, Lee KF, Hwang TZ, Jung SM, et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 2005; 27: 503-12. (Pubitemid 40770819)
10. Peng JP, Chang HC, Hwang CF, Hung WC. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasis. Oral Oncol 2005; 41: 903-8.
11. Chen PY, Long QC. Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 2004; 25: 943-9.
12. Chan CM, Ma BB, Wong SC, Chan AT. Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. Biomed Pharmacother 2005; 59: S268-71.
13. Chen J, Ran Y, Hong C, Chen Z, You Y. Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein. Cytotechnology 2010; 62: 431-8.
14. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65: 939-47. (Pubitemid 40216455)
15. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105. (Pubitemid 38198738)
16. Ma N, Kawanishi M, Hiraku Y, Murata M, Huang GW, Huang Y, et al. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression. Int J Cancer 2008; 122: 2517-25. (Pubitemid 351590485)
17. Liu YP, Tan YN, Wang ZL, Zeng L, Lu ZX, Li LL, et al. Phosphorylation and nuclear translocation of STAT3 regulated by the Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Int J Mol Med 2008; 21: 153-62. (Pubitemid 351222848)
18. Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 2009; 125: 1884-93.
19. Reed S, Li H, Li C, Lin J. Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. Biochem Biophys Res Commun 2011; 407: 450-5.
20. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431-41. (Pubitemid 35370756)
21. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 473-87. (Pubitemid 35370760)
22. Wang Z, Luo F, Li L, Yang L, Hu D, Ma X, et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 and ERK signaling. Eur J Cancer 2010; 46: 2996-3006.
23. Du CW, Wen BG, Li DR, Lin YC, Zheng YW, Chen L, et al. Latent membrane protein-1 of Epstein-Barr virus increases sensitivity to arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cell. Exp Oncol 2005; 27: 267-72. (Pubitemid 43139356)
24. Lin X, Liu S, Luo X, Ma X, Guo L, Li L, et al. EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells. Int J Cancer 2009; 124: 1020-7.
25. Jendrossek V. Targeting apoptosis pathways of celecoxib in cancer. Cancer Lett 2011; doi:10.1016/j.canlet.2011.01.012.
26. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 3351-5. (Pubitemid 34651376)
27. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11: 709-19. (Pubitemid 30030710)
28. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-62.
29. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137-44. (Pubitemid 32681546)
30. Kim KW, Mutter RW, Cao C, Albert JM, Shinohara ET, Sekhar KR, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther 2006; 5: 2659-65. (Pubitemid 44848992)
31. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550-60. (Pubitemid 38658421)
32. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552-60. (Pubitemid 43119350)
33. Gao LF, Wen LJ, Yu H, Zhang L, Meng Y, Shao YT, et al. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol Sin 2006; 27: 347-52. (Pubitemid 43357032)
34. Lui VW, Yau DM, Wong EY, Ng YK, Lau CP, Ho Y, et al. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009; 30: 2085-94.
35. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-21. (Pubitemid 41752912)
36. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005; 7: R422-35.
37. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004; 316: 421-8. (Pubitemid 38338610)
38. Liu B, Shi ZL, Feng J, Tao HM. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via downregulation of PI3K/Akt. Cell Biol Int 2008; 32: 494-501.
39. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98: 6905-10. (Pubitemid 32538315)
40. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositidedependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613-21. (Pubitemid 34966703)
41. Monick MM, Robeff PK, Butler NS, Flaherty DM, Carter AB, Peterson MW, et al. Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem 2002; 277: 32992-3000. (Pubitemid 34984814)
42. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
43. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
44. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007; 9: R32.
45. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 2005; 11: 1999-2007. (Pubitemid 40471866)
46. Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, et al. Celecoxib toxicity is cell cycle phase specific. Cancer Res 2007; 67: 3801-8. (Pubitemid 46762167)
47. Sobolewski C, Cerella C, Dicato M, Diederich M. Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells. Cell Cycle 2011; 10: 2978-93.
48. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331-42. (Pubitemid 23139228)
49. Handrick R, Ganswindt U, Faltin H, Goecke B, Daniel PT, Budach W, et al. Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax. Radiother Oncol 2009; 90: 413-21.
50. Klenke FM, Abdollahi A, Bischof M, Gebhard MM, Ewerbeck V, Huber PE, et al. Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol 2011; 187: 45-51.
51. Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011; 117: 3173-81.
52. Xue WP, Bai SM, Luo M, Bi ZF, Liu YM, Wu SK. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2011; 47: 753-7.